The relative contributions of the Genomic Prostate Score and comorbidity profile in predicting outcomes in surgically treated men with clinically low and intermediate-risk prostate cancer.

Jennifer Cullen,Dudith Pierre-Victor,H. Jeffrey Lawrence,Huai-Ching Kuo,Isabell A. Sesterhenn,Inger L. Rosner

The relative contributions of the Genomic Prostate Score and comorbidity profile in predicting outcomes in surgically treated men with clinically low and intermediate-risk prostate cancer.

2019

Jennifer Cullen
Dudith Pierre-Victor
H. Jeffrey Lawrence
Huai-Ching Kuo
Isabell A. Sesterhenn
Inger L. Rosner

e16607Background: The 17-gene Oncotype Dx Genomic Prostate Score® (GPS™) assay has been validated as a predictor of aggressive prostate cancer (PCa) in men treated with radical prostatectomy (RP) f...

Keywords:

Prostate cancer
Oncology
Prostate
Pathology
Internal medicine
Medicine
Comorbidity
Prostatectomy
intermediate risk
Oncotype DX

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations